Passa al contenuto
Merck
Tutte le immagini(1)

Documenti

B-044

Supelco

Buprenorphine solution

1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali
Tutte le immagini(1)

About This Item

Formula empirica (notazione di Hill):
C29H41NO4
Numero CAS:
52485-79-7
Peso molecolare:
467.64
Codice UNSPSC:
41116107
NACRES:
NA.24

Grado

certified reference material

Forma fisica

liquid

Caratteristiche

SNAP-N-SPIKE®, SNAP-N-SHOOT®

Confezionamento

ampule of 1 mL

Produttore/marchio commerciale

Cerilliant®

drug control

Narcotic Licence Schedule A (Switzerland); psicótropo (Spain); Decreto Lei 15/93: Tabela IIC (Portugal)

Concentrazione

1.0 mg/mL in methanol

tecniche

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

applicazioni

forensics and toxicology

Formato

single component solution

Temperatura di conservazione

−20°C

Stringa SMILE

CO[C@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]4Cc5ccc(O)c6O[C@@H]2[C@]3(CCN4CC7CC7)c56

InChI

1S/C29H41NO4/c1-25(2,3)26(4,32)20-15-27-10-11-29(20,33-5)24-28(27)12-13-30(16-17-6-7-17)21(27)14-18-8-9-19(31)23(34-24)22(18)28/h8-9,17,20-21,24,31-32H,6-7,10-16H2,1-5H3/t20-,21-,24-,26+,27-,28+,29-/m1/s1
RMRJXGBAOAMLHD-IHFGGWKQSA-N

Cerchi prodotti simili? Visita Guida al confronto tra prodotti

Descrizione generale

A Certified Spiking Solution® suitable for GC/MS or LC/MS applications in pain prescription monitoring, forensic testing, or clinical toxicology.

Buprenorphine is a semi-synthetic opioid that shows partial agonistic activity towards the μ-opioid receptor and antagonistic activity towards the kappa opioid receptor. And even though it is similar to morphine, it is more potent than morphine. The drug is sold under numerous trade names such as Suboxone®, Subutex®, and Temgesic.

Applicazioni

The certified reference solution (CRM) in solution can also be used as follows:
  • Multi-residue analysis of buprenorphine, norbuprenorphine, and naloxone in the fingernails and urine samples of previous heroin users under an opioid substitution therapy by solid-liquid or solid-phase extraction combined with liquid chromatography-mass spectrometry (LC-MS) for analysis
  • Liquid chromatography-electrospray ionization-tandem mass spectrometry (LC-ESI-MS/MS) based separation and determination of naloxone, buprenorphine, and norbuprenorphine in human plasma samples following their single-step liquid-liquid extraction (LLE)
  • Development of nanocomposite rhodium nanoparticles-mesoporous carbon (RhNPs-MC) for their deposition on glassy carbon electrode (GCE) to compose an electrochemical sensor for the measurement of morphine and buprenorphine in pharmaceutical formulations and human serum samples using differential pulse voltammetry (DPV)
  • Study of human blood plasma samples for the quantitative analysis of buprenorphine and naloxone by liquid chromatography (LC) coupled to high-resolution time-of-flight mass spectrometry (HR-Q-TOF-MS)
  • Simultaneous determination of buprenorphine, norbuprenorphine, and their glucuronides from human urine samples by ultra-high-performance liquid chromatography-tandem mass spectrometry (UHPLC-MS/MS)

Caratteristiche e vantaggi

  • Fully characterized under ISO/IEC 17025 and ISO 17034 accreditation
  • Accompanied with a comprehensive Certificate of Analysis (CoA) with data on stability, homogeneity, accuracy of concentration, uncertainty, and traceability
  • Rigorously tested through real-time stability studies to ensure accuracy and shelf life
  • Gravimetrically prepared using qualified precision balances to ensure minimal uncertainty
  • Flame sealed under argon into ampoules for long-term shelf life
  • Offered in a convenient, DEA-exempt format to improve laboratory efficiency

Note legali

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
CERTIFIED SPIKING SOLUTION is a registered trademark of Cerilliant Corporation
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany
Suboxone is a registered trademark of RB Pharmaceuticals Limited
Subutex is a registered trademark of RB Pharmaceuticals Limited

Prodotti correlati

N° Catalogo
Descrizione
Determinazione del prezzo

B-035

Buprenorphine glucuronide solution, 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

B-901

Buprenorphine-D4 solution, 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

B-902

Buprenorphine solution, 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

B-908

Buprenorphine-D4 solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

P-071

Pain Management Multi-component Opiate Mixture-13 solution, 100 μg/mL each component (10 μg/mL Fentanyl), ampule of 1.0 mL, certified reference material, Cerilliant®

N-045

Norbuprenorphine glucuronide solution, 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

N-059

Norbuprenorphine solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

N-912

Norbuprenorphine solution, 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

N-920

Norbuprenorphine-D3 solution, 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

N-921

Norbuprenorphine-D3 solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

B-100

Buprenorphine-D9 solution, 1 mg/mL in methanol, certified reference material, ampule of 1 mL, Cerilliant®

B-101

Buprenorphine-D9-3-beta-D-glucuronide solution, 100 μg/mL in methanol, certified reference material, ampule of 1 mL, Cerilliant®

N-145

Norbuprenorphine-D9 solution, 1 mg/mL in methanol, certified reference material, ampule of 1 mL, Cerilliant®

N-146

Norbuprenorphine-D9-3-beta-D-glucuronide solution, 100 μg/mL in methanol, certified reference material, ampule of 1 mL, Cerilliant®

B-044S

Buprenorphine solution, 1 mg/mL in methanol, certified reference material, ampule of 1 mL, Cerilliant®

Avvertenze

Danger

Indicazioni di pericolo

H225,H301 + H311 + H331,H370

Classi di pericolo

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

Organi bersaglio

Eyes,Central nervous system

Codice della classe di stoccaggio

3 - Flammable liquids

Classe di pericolosità dell'acqua (WGK)

WGK 2

Punto d’infiammabilità (°F)

49.5 °F - closed cup

Punto d’infiammabilità (°C)

9.7 °C - closed cup

Certificati d'analisi (COA)

Cerca il Certificati d'analisi (COA) digitando il numero di lotto/batch corrispondente. I numeri di lotto o di batch sono stampati sull'etichetta dei prodotti dopo la parola ‘Lotto’ o ‘Batch’.

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

K Wahle et al.
MMW Fortschritte der Medizin, 155 Suppl 1, 25-31 (2013-05-18)
Chronic pain in the elderly is common. Especially in the elderly inadequate treatment of pain can cause significant functional impairmentand deterioration of qualityof life. Theaim of this post-marketing surveillance study was to collect data from clinical practice on the analgesic
Jatinder Mohan Chawla et al.
Journal of opioid management, 9(1), 35-41 (2013-05-28)
Tramadol is a synthetic opiate and a centrally acting weak m-opioid receptor agonist. The potential advantages of tramadol include ease of administration, low abuse potential, and being nonscheduled. This study compared tramadol and buprenorphine for controlling withdrawal symptoms in patients
O Bouab et al.
Revue medicale de Bruxelles, 34(3), 132-140 (2013-08-21)
Assess the effectiveness of hospital detoxification of opiate substitution treatment (OST) in patients who failed to withdraw as outpatients. Retrospective study, conducted among patients admitted for withdrawal of OST in an addiction unit between 2005 and 2011. Referent physicians were
Karen L Cropsey et al.
Journal of addiction medicine, 7(3), 210-215 (2013-04-24)
This project sought to demonstrate the feasibility and acceptability of providing on-site buprenorphine treatment to individuals under community corrections supervision. Seventeen women and 13 men were enrolled on-site over a 2-week period at a community corrections location. Study participants received
Johan Menten et al.
Cancer investigation, 31(6), 412-420 (2013-06-14)
Many head and neck cancer (HNC) patients experience painful therapy-related mucositis and dermatitis. This prospective observational study evaluated transdermal buprenorphine use in HNC patients to relieve treatment-related pain. During treatment with paracetamol or tramadol, visual analogue scale (VAS)-pain scores >30/100
Visualizza tutti i documenti correlati

Articoli

Benefits of Ascentis Express Phenyl-Hexyl over Biphenyl for the Separation of Pain Management Opiates

Although both biphenyl and phenyl-hexyl phases can resolve these compounds, the former exhibits excellent peak shape and substantially less silanol-derived ion exchange activity.

Protocolli

LC/MS (TOF) Analysis of Drugs and Their Glucuronide Metabolites in Urine on Titan™ C18 After Solid Phase Extraction (SPE) Using Supel™-Select SCX, β-Glucuronidase Enzyme Digestion

-THC solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material

UHPLC/MS for Drug Detection in Urine

Optimize β-glucuronidase hydrolysis for glucuronide metabolite analysis considering factors like time, temperature, pH, and enzyme concentration.

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.